National Center for Advancing Translational Sciences; Notice of Closed Meetings, 28081-28082 [2017-12752]
Download as PDF
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 117 / Tuesday, June 20, 2017 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cardiovascular Sciences.
Date: July 13–14, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Solamar, 435 6th Avenue, San
Diego, CA 92101.
Contact Person: Margaret Chandler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4126,
MSC 7814, Bethesda, MD 20892, (301)435–
1743, margaret.chandler@nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group; HIV/
AIDS Vaccines Study Section.
Date: July 13, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, DC, 2401
M Street NW., Washington, DC 20037.
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–435–0000,
bdey@mil.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Neuroscience Assay, Diagnostics
and Animal Model Development.
Date: July 13, 2017.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The St. Regis Washington DC, 923
16th Street NW., Washington, DC 20006.
Contact Person: Susan Gillmor, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Bethesda, MD 20892, 301–
435–1730, susan.gillmor@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Biochemistry and Biophysics of Biological
Macromolecules Fellowship Applications.
Date: July 13, 2017.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Sudha Veeraraghavan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–435–1504,
sudha.veeraraghavan@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; The BloodBrain Barrier, Neurovascular Systems and
CNS Therapeutics.
Date: July 13, 2017.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Linda MacArthur, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
VerDate Sep<11>2014
18:01 Jun 19, 2017
Jkt 241001
Health, 6701 Rockledge Drive, Room 4187,
Bethesda, MD 20892, 301–537–9986,
macarthurlh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Molecular Neurogenetics.
Date: July 13, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Paek-Gyu Lee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4201,
MSC 7812, Bethesda, MD 20892, (301) 613–
2064, leepg@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Receptors, Channels and Circuits.
Date: July 13, 2017.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Afia Sultana, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Bethesda, MD 20892, (301)
827–7083, sultanaa@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Health Services Organization and
Delivery.
Date: July 13, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Yvonne Owens Ferguson,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive Room 3139,
Bethesda, MD 20892, 301–827–3689,
fergusonyo@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 14, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–12750 Filed 6–19–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
28081
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; CTSA Program Data to
Health Coordinating Center (U24).
Date: July 17, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, Room 206, 6701
Democracy Boulevard, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, Office of Scientific
Director, National Center for Advancing
Translational Sciences (NCATS), National
Institutes of Health, 6701 Democracy Blvd.,
Democracy 1, Room 1080, Bethesda, MD
20892–4878, 301–451–2405, henriquv@
mail.nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; NCATS Pilot Program for
Collaborative Drug Discovery Research using
Bioprinted Skin Tissue (U18): RFA–TR–17–
007.
Date: July 19, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, Room 1087, 6701
Democracy Boulevard, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Rahat (Rani) Khan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, 6701 Democracy
Blvd., Rm 1078, Bethesda, MD 20892, 301–
894–7319, khanr2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
E:\FR\FM\20JNN1.SGM
20JNN1
28082
Federal Register / Vol. 82, No. 117 / Tuesday, June 20, 2017 / Notices
Dated: June 14, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–12752 Filed 6–19–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer at (240) 276–1243.
Project: Strategic Prevention
Framework for Prescription Drugs
(SPF-Rx)—New
The Substance Abuse and Mental
Health Services Administration
(SAMHSA)’s Center for Substance
Abuse Prevention (CSAP) aims to
conduct a cross-site evaluation of the
Strategic Prevention Framework for
Prescription Drug (SPF-Rx) program.
The SPF-Rx program is designed to
address nonmedical use of prescription
drugs (as well as) opioid overdoses by
raising awareness about the dangers of
sharing medications and by working
with pharmaceutical and medical
communities. The SPF-Rx program aims
to promote collaboration between states/
tribes and pharmaceutical and medical
communities to understand the risks of
overprescribing to youth age 12–17 and
adults 18 years of age and older. The
program also aims to enhance capacity
for, and access to, Prescription Drug
Monitoring Program (PDMP) data for
prevention purposes.
The SPF-Rx program aims to address
SAMHSA’s priorities on prevention and
reduction of prescription drug and illicit
opioid misuse and abuse. Its indicators
of success are reductions in opioid
overdoses and the incorporation of
PDMP data into needs assessments and
strategic plans. Data collected through
the tools described in this statement
will be used for the national cross-site
evaluation of SAMHSA’s SPF-Rx
program. This package covers continued
data collection through 2020, as the
evaluation is expected to continue
through at least that time; however, the
Program Evaluation for Prevention
Contract (PEP–C) is scheduled to
conduct a national cross-site evaluation
of SPF-Rx through September 2018. The
PEP–C team will systematically collect
and maintain an Annual
Implementation Instrument (AII) and
outcomes data submitted by SPF-Rx
grantees through the online PEP–C
Management Reporting Tool (MRT).
SAMHSA is requesting approval for
data collection for the SPF-Rx cross-site
evaluation with the following four
instruments:
• Grantee Interview to obtain the
perspective of the implementing Project
Directors (PDs) or their staff on
important topics, including
infrastructure and capacity,
collaboration, leveraging funding and
resources, criteria and use of evidenceinformed interventions, monitoring and
evaluation, collaboration, challenges,
and health disparities. Information from
these interviews will help inform SPFRx cross-site evaluation reports and will
help identify lessons learned and
success stories from grantees’ SPF-Rx
programs.
• Grantee- and Community-Level
Outcomes Modules to collect data on
key SPF-Rx program outcomes,
including opioid misuse and abuse,
opioid overdoses, and opioid
prescribing patterns. Grantees will
provide outcomes data at the grantee
level for their state, tribal area, or
jurisdiction, as well as at the
community level for each of their
subrecipient communities.
• Substitute Data Source Request to
allow grantees to request permission
from SAMHSA to use ‘‘substitute
measures’’ for their outcomes data—that
is, measures that differ from a list of
preapproved outcomes measures.
• Annual Implementation Instrument
to collect data completed by grantees
and subrecipient community PDs. Data
collected from the survey will be used
to monitor subrecipient and state, tribal
entity, or jurisdiction performance and
to evaluate the effectiveness of the SPFRx program across states, tribal entities,
and jurisdictions.
• Grantee Interview to collect
semistructured telephone interview data
to gather more in-depth information on
organizational infrastructure, use of
PDMP data, collaboration, leveraging of
funds and resources, and evaluation
activities
• Evaluation Plan to allow grantees to
outline their local evaluation plan.
Sections include goals and objectives,
performance measures, data analysis
plan, and reporting plan.
ANNUALIZED DATA COLLECTION BURDEN
Number of
respondents
Instrument
Responses
per
respondent
Total
number of
responses
Hours per
response
Total burden
hours
25
25
12
100
17
25
1
1
1
1
1
1
25
25
12
100
17
25
3
3
1
2.3
1.5
8
75
75
12
230
25.5
200
Overall Total .................................................................
sradovich on DSK3GMQ082PROD with NOTICES
Grantee-Level Outcomes Module ........................................
Community-Level Outcomes Module ...................................
Substitute Data Request Form ............................................
Annual Implementation Instrument ......................................
Grantee-Level Interview .......................................................
Evaluation Plan ....................................................................
100
........................
204
........................
618
Note. Annualized Data Collection Burden captures the average number of respondents and responses, burden hours, and respondent cost
over the 3 years (FY2018–FY2020).
Written comments and
recommendations concerning the
proposed information collection should
be sent by July 20, 2017 to the SAMHSA
Desk Officer at the Office of Information
VerDate Sep<11>2014
18:01 Jun 19, 2017
Jkt 241001
and Regulatory Affairs, Office of
Management and Budget (OMB). To
ensure timely receipt of comments, and
to avoid potential delays in OMB’s
receipt and processing of mail sent
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
E:\FR\FM\20JNN1.SGM
20JNN1
Agencies
[Federal Register Volume 82, Number 117 (Tuesday, June 20, 2017)]
[Notices]
[Pages 28081-28082]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12752]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; CTSA Program Data to Health
Coordinating Center (U24).
Date: July 17, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, One Democracy Plaza, Room
206, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Victor Henriquez, Ph.D., Scientific Review
Officer, Office of Scientific Director, National Center for
Advancing Translational Sciences (NCATS), National Institutes of
Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD
20892-4878, 301-451-2405, henriquv@mail.nih.gov.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; NCATS Pilot Program for
Collaborative Drug Discovery Research using Bioprinted Skin Tissue
(U18): RFA-TR-17-007.
Date: July 19, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, One Democracy Plaza, Room
1087, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Rahat (Rani) Khan, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Center for Advancing
Translational Sciences, 6701 Democracy Blvd., Rm 1078, Bethesda, MD
20892, 301-894-7319, khanr2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
[[Page 28082]]
Dated: June 14, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-12752 Filed 6-19-17; 8:45 am]
BILLING CODE 4140-01-P